ABVC Biopharma Inc
NASDAQ:ABVC
ABVC Biopharma Inc
NASDAQ:ABVC
Price:
1.08 USD
-6.09%
Market Closed
Updated:
May 5, 2024
ABVC Biopharma Inc
Cash from Financing Activities
|
ABVC Biopharma Inc
Cash from Financing Activities Peer Comparison
Comparables:
AMGN
ALNY
KRTX
MRNA
SRPT
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ABVC Biopharma Inc
NASDAQ:ABVC
|
Cash from Financing Activities
$3.9m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Cash from Financing Activities
$172.1m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
21%
|
CAGR 10-Years
-2%
|
|
|
Karuna Therapeutics Inc
NASDAQ:KRTX
|
Cash from Financing Activities
$483.4m
|
CAGR 3-Years
409%
|
CAGR 5-Years
77%
|
CAGR 10-Years
N/A
|
|
|
Moderna Inc
NASDAQ:MRNA
|
Cash from Financing Activities
-$1.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sarepta Therapeutics Inc
NASDAQ:SRPT
|
Cash from Financing Activities
$45.3m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-11%
|
See Also
What is ABVC Biopharma Inc's Cash from Financing Activities?
Cash from Financing Activities
3.9m
USD
3.9m
USD
Based on the financial report for Dec 31, 2023, ABVC Biopharma Inc's Cash from Financing Activities amounts to 3.9m USD.
What is ABVC Biopharma Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
34%
34%
Over the last year, the Cash from Financing Activities growth was -2%. The average annual Cash from Financing Activities growth rates for ABVC Biopharma Inc have been -26% over the past three years , 34% over the past five years .
You don't have any saved screeners yet
